Allogeneic bone marrow transplantation in myelofibrosis (program ID: 149253)
University Hospital of Ludwig Maximilian University of Munich
Michael von BergweltSpecialized in: oncology, hematology
Department of Oncology and Hematology
- Initial presentation in the clinic
- case history collection
- general clinical examination
- laboratory tests:
- complete blood count
- biochemical analysis of blood
- TSH-basal, fT3, fT4
- differential blood count
- inflammation indicators (CRP, ESR)
- indicators of blood coagulation
- CT/MRI scans of the whole body
- needle biopsy of the bone marrow
- biopsy and histological examination of CSF
- examination by experts of:
- registration in the European bone marrow donor base
- conducting high-dose chemotherapy
- allogeneic bone marrow transplantation from
- the cost of blood products
- isolation by neutropenic precautions
- symptomatic treatment
- control examinations
- the cost of essential medicines and materials
- nursing services
- full hospital accommodation
- explanation of future recommendations
How program is carried out
During the first visit, the doctor will conduct a clinical examination and go through the results of the available diagnostic tests. After that, you will undergo the necessary additional examination, such as the assessment of liver and kidney function, ultrasound scan, CT scan and MRI.
Also, the doctor will conduct a bone marrow biopsy followed by cytological examination of the harvested material. This will help him to determine the histological features of your bone marrow (in particular, identify HLA system antigens) and select a suitable donor. The donor can be a family member or a person from the bone marrow registry. In the second case, the donor material is stored in a bone marrow bank.
Before the procedure, you will receive chemotherapy, if necessary in combination with radiation therapy. The course of chemo- or chemoradiation therapy lasts from 2 to 8 days.
The bone marrow transplant procedure is an intravenous infusion, i.e. the healthy bone marrow will be injected through a catheter, intravenously. You will stay in your room during the procedure. A bone marrow transplant is completely painless and does not require anesthesia.
During the period of healthy bone marrow engraftment, you will stay in a sterile ward. This is a necessary precaution because during this time your immune system is very weak and cannot withstand environmental pathogens. The risk of bleeding is also quite high, so you will be advised to avoid mechanical damage.
A relative or other close person may stay in the ward with you. You will not be allowed to go outside the department and leave your ward often. The rehabilitation period can last from 1 to 2 months.
When your complete blood count returns to normal, your doctor will schedule your discharge from the department. You will receive information about the rules that you will need to follow at home, the frequency and type of control examinations, and subsequent treatment measures. You will also receive a detailed medical report, which will reflect the entire course of treatment.
- Medical records
- Bone marrow biopsy results (if available)
You may also book
About the department
175 Booking Health patients have already received treatment in the Department of Oncology and Hematology at the University Hospital of Ludwig Maximilian University of Munich.
99% of patients recommend this hospital and department.
You can read reviews about the quality of the Booking Health service here.
The Department of Oncology and Hematology at the University Hospital of Ludwig Maximilian University of Munich offers the full range of services in the field of diagnostics and treatment of oncological and blood diseases. Of particular interest is the treatment of patients with acute leukemia, lymphomas, carcinomas and sarcomas. The highly qualified medical team of 65 doctors and 130 nurses takes care of the health of the patients. About 2,800 inpatients and 10,000 outpatients are treated in the department annually. The Chief Physician of the department is Prof. Dr. Dr. Michael von Bergwelt.
The innovative method of hyperthermia is applied in the department for the treatment of malignant tumors, the effectiveness of which is internationally recognized. In addition, the department has two modern units for allogeneic stem cell transplantation (bone marrow transplantation). Psycho-oncological care is also a significant aspect of the therapy.
The service range of the department includes the diagnostics and treatment of the following diseases:
- 1988 - 1996 Study of Medicine at the Universities of Freiburg, Muenster and Paris (University of Paris-South XI)
- 1996 Admission to medical practice
- 1994 - 1996 Study of Human Biology at the University of Paris-South XI
- 1996 Master in Biological and Medical Sciences (MSBM, Maitrise de Sciences Biologiques et Medicales)
- 1996 Examination for the US medical license (USMLE), I and II parts
- 1997 Thesis for the degree of Doctor of Medicine. Subject: "Phenotypic and functional characteristics of lymphocyte infiltrating tumor in patients with colorectal carcinoma stimulated by interleukin-2 and interleukin-4 in vitro" (University of Freiburg).
- 1997 - 1999 Internship, Department of Internal Medicine I (Head: Prof. Volker Diehl)
- 1999 Certification in Emergency Medicine, Lower Saxony
- 1999 - 2002 Postdoctoral Fellow, Dana-Farber Cancer Institute, Harvard Medical School, Boston
- 2002 Thesis for the degree of Dr. rer. nat. Subject: "Biological and biotechnological analysis of antigen-presenting B-cells activated by CD40" (with honors, University of Oldenburg)
- 2002 - 2007 Internship and scholarship, Department of Internal Medicine I, University of Cologne (Head: Prof. Michael Hallek)
- 2003 - 2009 Head, Max-Eder Junior Research Group, German Cancer Society
- 2006 Certification in Internal Medicine, Hematology and Oncology
- 2007 Venia Legendi in Internal Medicine ("Analysis of the use of the antigen-presenting function of B cells for tumor immunotherapy")
- 2008 Certification in Intensive Care
- 2008 Director of the Cologne Interventional Immunology Project and Scientific Director of the Stem Cell Transplant Program
- 2009 Certification in Infectiology
- 2011 Leading Senior Physician
- 2012 Adjunct Professor in Internal Medicine, University of Cologne
- 2012 Professor and Head of Hematology Сourse, Ronald Finn Department of Experimental Medicine, University of Liverpool (rejection)
- 2015 CARTime Research Consortium (CAR T-Cell Clinical Study in Melanoma), Research Coordinator from the German Federal Ministry of Education and Research (BMBF)
- 2016 Research Consortium of the German Cancer Society (DKH) "Inhibition of control points of the immune response in Hodgkin's lymphoma", Head of the Section of Tumor Immunology
- Since 2017 Head of the Department of Oncology and Hematology, University Hospital of Ludwig Maximilian University of Munich
Awards, Honors and Memberships
- 2015 Best Abstract Award of the German Society of Hematology and Oncology DGHO (co-author)
- 2010 Travel Award of the American Society for Bone Marrow Transplantation
- 2010 Basic Science Award (O84 Abstracts, co-author) of the European Society for Blood and Marrow Transplantation
- 2002 Member of the Josep Carreras Leukaemia Foundation, Germany
- 2001 Member of the American Lymphoma Research Foundation
- 1999 Travel Award of the American Society of Hematology
- 1999 EMSA Science Award, University of Prague
- 1999-1997 Member of the Mildred Scheel Foundation, German Cancer Society, University of Prague
Photo of the doctor: (c) LMU Klinikum
Accommodation in hospital
- Program [Description]
Allogeneic bone marrow transplantation in myelofibrosis
- Hospital: University Hospital of Ludwig Maximilian University of Munich
There are 33 myelofibrosis treatment hospitals on Booking Health websiteShow all clinics